Online citations, reference lists, and bibliographies.

Hope And Challenge: Precision Medicine In Bladder Cancer

Hongwei Su, Haitao Jiang, Tao Tao, Xing Kang, Xu Zhang, D. Kang, Shucheng Li, Chengxi Li, Haifeng Wang, Zhao Yang, J. Andrew Zhang, Chong Li
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Bladder cancer (BC) is a complex disease and could be classified into nonmuscle‐invasive BC (NMIBC) or muscle‐invasive BC (MIBC) subtypes according to the distinct genetic background and clinical prognosis. Until now, the golden standard and confirmed diagnosis of BC is cystoscopy and the major problems of BC are the high rate of recurrence and high costs in the clinic. Recent molecular and genetic studies have provided perspectives on the novel biomarkers and potential therapeutic targets of BC. In this article, we provided an overview of the traditional diagnostic approaches of BC, and introduced some new imaging, endoscopic, and immunological diagnostic technology in the accurate diagnosis of BC. Meanwhile, the minimally invasive precision treatment technique, immunotherapy, chemotherapy, gene therapy, and targeted therapy of BC were also included. Here, we will overview the diagnosis and therapy methods of BC used in clinical practice, focusing on their specificity, efficiency, and safety. On the basis of the discussion of the benefits of precision medicine in BC, we will also discuss the challenges and limitations facing the non‐invasive methods of diagnosis and precision therapy of BC. The molecularly targeted and immunotherapeutic approaches, and gene therapy methods to BC treatment improved the prognosis and overall survival of BC patients.
This paper references
10.3322/canjclin.49.1.33
Global cancer statistics.
Donald Maxwell Parkin (1999)
10.1111/bju.13020
Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Juan Palou (2015)
10.1016/j.eururo.2010.10.008
Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer.
David Margel (2011)
10.1089/end.2009.0171
Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer.
Song Xi-shuang (2010)
10.1016/j.juro.2015.02.663
PD17-06 RANDOMIZED PHASE II TRIAL OF INTRAVESICAL ADENOVIRAL MEDIATED INTERFERON-α GENE THERAPY WITH THE EXCIPIENT SYN3 (RAD-IFNα/SYN3) IN PATIENTS WITH BCG REFRACTORY OR RELAPSING HIGH GRADE (HG) NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Daniel J. Canter (2015)
10.1016/j.juro.2013.03.030
Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
Colin P. N. Dinney (2013)
Novel endoscopic diagnosis for bladder
SP Lerner (2015)
10.1038/nature12965
Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma
The Cancer Genome Atlas Research Network (2014)
10.1016/j.eururo.2015.06.023
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
Ashish M. Kamat (2016)
10.1073/PNAS.1610472113
Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo
Jovana Golijanin (2016)
10.20892/j.issn.2095-3941.2016.0020
Nonmuscle invasive bladder cancer: a primer on immunotherapy
Mahir Maruf (2016)
10.1038/nrurol.2011.145
C-reactive protein as a biomarker for urological cancers
Kazutaka Saito (2011)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1002/lsm.22565
Green-light laser en bloc resection for primary non-muscle-invasive bladder tumor versus transurethral electroresection: A prospective, nonrandomized two-center trial with 36-month follow-up.
Ji Chen (2016)
10.1016/j.eururo.2016.06.010
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
Sébastien Antoni (2017)
10.1007/s00345-016-1795-5
Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study
Michael D. Bell (2016)
10.1016/j.eururo.2016.03.053
The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Proto
Seiji Prof Naito (2016)
10.1002/cncr.29387
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Matthew D Galsky (2015)
10.1371/journal.pone.0141253
Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics
Céu Clara Costa (2015)
Adenoviralmediated p53 gene transfer in advanced non‐small cell lung cancer
SG Swisher (1999)
10.1016/j.ucl.2015.02.002
Trimodality therapy in bladder cancer: who, what, and when?
Christopher Premo (2015)
10.18632/oncotarget.19112
Bladder cancer stem cells: clonal origin and therapeutic perspectives
Yi Li (2017)
10.1016/j.eururo.2016.06.025
Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells.
Zhao bo Yang (2017)
10.1111/bju.12355
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
Timothy O'Brien (2013)
10.4161/cbt.5.4.2509
Characterization of a novel transplantable orthotopic murine xenograft model of a human bladder transitional cell tumor (BIU-87)
Li Chong (2006)
10.1002/cam4.802
A novel hedgehog inhibitor iG2 suppresses tumorigenesis by impairing self‐renewal in human bladder cancer
Lihong Zhu (2016)
10.18632/ONCOTARGET.4295
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer
Chong Li (2015)
10.1016/j.eururo.2014.06.037
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
J. Alfred Witjes (2014)
10.1038/nature13904
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles (2014)
10.1016/j.eururo.2016.10.018
Robotic Intracorporeal Padua Ileal Bladder: Surgical Technique, Perioperative, Oncologic and Functional Outcomes.
Giuseppe Simone (2018)
Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
New NRCU (2011)
10.18632/oncotarget.6380
Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing
Song Wu (2016)
10.1158/1078-0432.CCR-13-3397
BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Chong Li (2014)
10.1007/s00259-016-3500-8
Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT
Pierpaolo Alongi (2016)
10.3892/MCO.2013.85
ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy.
Shigeru Sakano (2013)
10.1200/JCO.1998.16.6.2221
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.
Gary L Clayman (1998)
10.1158/1535-7163.MCT-15-0140
Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer
Kazuyuki Yuge (2015)
10.1073/pnas.1424795112
CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer
Ming T. Cheah (2015)
10.1016/j.ejrad.2011.07.018
Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis.
Yu-Yu Lu (2012)
10.1016/j.juro.2016.10.101
INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS
Alvaro Morales (2017)
10.1158/1078-0432.CCR-17-0882
The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells
Zhao Yang (2017)
10.1097/RLU.0000000000001367
Unexpected Detection of Urinary Bladder Cancer on Dual Phase 18F-NaF PET/CT in a Patient With Back Pain.
Fuqiang Shao (2016)
10.1007/s11934-016-0579-1
A Review Comparing Experience and Results with Bipolar Versus Monopolar Resection for Treatment of Bladder Tumors
Yasser Osman (2016)
10.1016/j.ejca.2016.06.003
A five-gene expression signature to predict progression in T1G3 bladder cancer.
Antoine G. van der Heijden (2016)
Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis.
Mingxia Ding (2015)
10.2147/OTT.S65367
Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro
Shouxin Wang (2014)
10.1016/j.redox.2015.08.008
Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes☆
Charlotta Ryk (2015)
10.1016/j.eururo.2015.02.040
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Luís Martínez-Piñeiro (2015)
10.1089/pho.2015.3913
Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study.
Xin-ru Zhang (2015)
10.1016/j.eururo.2013.12.003
Long noncoding RNA in prostate, bladder, and kidney cancer.
Elena S. Martens-Uzunova (2014)
10.1016/j.ctrv.2016.09.018
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
Rafael Morales-Bárrera (2016)
10.1126/scitranslmed.3009457
Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
Ying Pan (2014)
10.1016/0092-8674(93)90719-7
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Scott W. Lowe (1993)
10.1080/14737159.2016.1244006
Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence
L M Krabbe (2016)
10.1158/1078-0432.CCR-15-1208
Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
Hyung Suk Kim (2015)
10.1371/journal.pone.0131245
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
Alexander S. Baras (2015)
10.1016/j.eururo.2015.01.014
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Floris H Groenendijk (2016)
10.7326/M15-0997
Urinary Biomarkers for Diagnosis of Bladder Cancer
Roger Chou (2015)
10.1056/NEJMp1500523
A new initiative on precision medicine.
Francis S. Collins (2015)
10.18632/oncotarget.13504
BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor
Chong Li (2017)
10.1089/end.2013.0740
Novel green-light KTP laser en bloc enucleation for nonmuscle-invasive bladder cancer: technique and initial clinical experience.
Dalin He (2014)
10.1259/bjr/99567374
Investigating the relationship between virtual cystoscopy image quality and CT slice thickness.
Susan Lalondrelle (2012)
10.1186/1741-7015-11-104
Advances in bladder cancer imaging
Shaista Hafeez (2013)
10.1016/j.urolonc.2015.03.019
Promises and challenges of fluorescence cystoscopy.
Yair Lotan (2015)
10.1016/j.eururo.2014.07.033
Inflammatory biomarkers and bladder cancer prognosis: a systematic review.
Alexandra Masson-Lecomte (2014)
10.1186/2193-1801-3-519
The role of transcavitary ultrasonography in diagnosis and staging of nonmuscle-ınvasive bladder cancer: a prospective non-randomized clinical study
Gultekin Cagri Oktem (2014)
[Neoadjuvant chemotherapy for invasive bladder cancer].
Yukio Kageyama (2001)
10.1016/j.urolonc.2016.08.019
Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
Philip H. Abbosh (2016)
10.1073/pnas.88.12.5257
The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells.
Rei Takahashi (1991)
10.1016/j.eururo.2014.12.008
Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
Bertram E. Yuh (2015)
10.1016/j.eururo.2017.03.030
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Roland Seiler (2017)
10.1016/j.eururo.2015.05.050
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from
Richard J. Sylvester (2016)
10.3322/caac.21262
Global cancer statistics, 2012.
Lindsey A. Torre (2015)
10.1016/j.ccr.2014.01.009
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Woonyoung Choi (2014)
10.1016/j.eururo.2016.11.003
Reply from Authors re: Xue-Ru Wu. Attention to Detail by Single-cell sequencing. Eur Urol 2017;71:13-4.
Zhao Yang (2017)
10.1158/0008-5472.CAN-15-2309
GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
Chong Li (2016)
10.3389/fphys.2014.00097
Targeting diseased tissues by pHLIP insertion at low cell surface pH
Oleg A Andreev (2014)
10.1016/j.pdpdt.2015.12.011
The clinical trial on the safety and effectiveness of the photodynamic diagnosis of non-muscle-invasive bladder cancer using fluorescent light-guided cystoscopy after oral administration of 5-aminolevulinic acid (5-ALA).
Keiji Inoue (2016)
Hope and challenge: Precision medicine in bladder cancer
H Su (2019)
10.1056/NEJMp1114866
Preparing for precision medicine.
Reza Mirnezami (2012)
10.4103/0970-1591.166446
Intravesical chemotherapy in non-muscle-invasive bladder cancer
Sima P. Porten (2015)
10.1016/j.eururo.2016.05.041
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Marko Babjuk (2017)
10.1186/s12885-016-2748-5
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer
Jean-Pierre Roperch (2016)
10.1016/j.urolonc.2016.05.013
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Aurélie Mbeutcha (2016)
10.1016/j.urolonc.2014.06.008
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Faysal A. Yafi (2015)
10.1016/j.clgc.2015.03.002
High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Kenji Tanabe (2015)
Reply from Authors re: Xue‐Ru Wu. Attention to detail by single‐cell sequencing
Z Yang (2017)
10.1038/NATURE12965
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein (2014)
10.1093/jnci/91.9.763
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
Stephen G. Swisher (1999)
10.1016/j.eururo.2014.12.027
Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel.
K. Gary Chan (2015)
10.1111/j.1464-410X.2011.10706.x
Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
Hiroshi Miyamoto (2012)
10.1177/0300060515621445
Comparison of the clinical effectiveness of 3D and 2D imaging systems for laparoscopic radical cystectomy with pelvic lymph node dissection
Feng Tang (2016)
Greene Intravesical chemotherapy in non ‐ muscle ‐ invasive bladder cancer
RJ Sylvester (2015)
10.1016/j.urolonc.2016.05.012
Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Edmund C P Chedgy (2016)
10.1016/j.eururo.2013.10.038
Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
Songnian Wu (2014)
10.1097/MOU.0000000000000337
Cancer immunotherapy: new applications in urologic oncology
Stephanie A. Mullane (2016)
10.1016/j.eururo.2013.10.016
Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.
Ashish M. Kamat (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar